| Glucagon-Like Peptide-1 (GLP-1) Agonist |
|
Young Sil Eom, Byung-Joon Kim |
|
Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea |
| 글루카곤양 펩티드-1 유사체 |
|
엄영실, 김병준 |
|
가천대학교 길병원 내과 |
Correspondence:
Byung-Joon Kim, Tel: +82-32-460-8903, Fax: +82-32-469-4320, Email: kbjoon4u@gilhospital.com
|
|
|
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits
unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Abstract |
|
The prevalence of diabetes is increasing worldwide. Glycemic control has been shown to prevent microvascular complications.
Many oral hyperglycemic drugs and insulin are being used in the treatment of diabetes, but the effects of those treatments are
suboptimal. The two incretin hormones GLP-1 and GIP are released from L- and K-cells, respectively, in response to nutrient
intake. GLP-1 stimulates glucose-dependent insulin release. Recently, incretin hormone-based therapies, including GLP-1 agonists
and DPP-4 inhibitors, have been used as new treatment options to control glucose levels in patients with type 2 diabetes mellitus.
The purpose of this article is to review the efficacy and safety of GLP-1 agonists in the treatment of type 2 diabetes. |
| Key Words:
Glucagon-like peptide 1 analogue; Incretin; Type 2 diabetes |
|
PDF Links
Full text via DOI
Download Citation
